SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
Important Safety Information
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.
Warnings and Precautions
- Gastrointestinal: SANCUSO may mask a progressive ileus and/or gastric distention caused by the underlying condition.
- Serotonin syndrome: SANCUSO is a serotonin -3 (5-HT3) receptor antagonist. Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone and particularly with concomitant use of serotonergic drugs. Avoid prescribing additional products that contain granisetron or other serotonergic drugs.
- Skin reactions: Mild application-site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.
- External heat sources: Patients should avoid exposing the SANCUSO patch and surrounding area to direct external heat sources, such as heating pads, as plasma concentration continues increasing during the period of heat exposure.
- Exposure to sunlight: Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it because of potential skin reaction.
The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).
To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-SANCUSO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See full Prescribing Information for SANCUSO.